2007 Annual Report - Foundation for the National Institutes of Health

More documents

Recommendations

Info

ADNI: Alzheimer’s Disease Neuroimaging Initiative First described more than 100 years ago, Alzheimer’s disease has no cure or lasting, effective treatment. More than 4 million people in the United States suffer from it and its incidence is projected to increase dramatically over the next 20 years. The goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to alter that prognosis. The NIH’s largest public-private partnership on brain research, this five-year study tracks normal, mildly cognitively impaired, and Alzheimer’s disease brain changes to measure progression of the condition. The initiative completed enrollment in August 2007. Using MRI and PET imaging and laboratory and cognitive tests, the study monitors 823 participants over two to three years, building a comprehensive database as it goes. This catalog will serve as an important public resource to spur further research. Already, many of the tools and methods developed by the study are fueling efforts in Japan, the European Union, and Australia. Conducted by the National Institute on Aging (NIA) in conjunction with more than a dozen other federal agencies and private-sector companies and organizations, this $60 million effort has relied on the Foundation for NIH to raise nearly $25 million. In 2007, additional funds were secured to conduct a genome-wide association study and analysis of ADNI participants. This effort will provide the most extensive and robust dataset of its kind in the Alzheimer’s disease field. A second supplement to the study allows for the collection of cerebrospinal fluid from participants, while a third explores the use of PET and Pittsburg Compound B (PIB) as a tool for developing biochemical markers. Contributors to adni include Alzheimer’s Association GlaxoSmithKline AstraZeneca LP Innogenetics Bristol-Myers Squibb Company Cure Alzheimer’s Fund Eisai Inc. Elan Pharmaceuticals Eli Lilly & Company GE Healthcare Gene Network Sciences Institute for the Study of Aging Merck & Co., Inc. Novartis Pfizer Inc Wyeth “Working with the Foundation for NIH has made it possible to expand the horizons of genome research well beyond what NIH could do alone. Everyone agrees that public-private partnerships are critical to our future —but the Foundation for NIH makes those a reality!” —Francis Collins, M.D., Ph.D. Director, National Human Genome Research Institute at NIH 8 | 2007 Annual report
GAIN: Genetic Association Information Network In 2007, the Genetic Association Information Network (GAIN) completed an ambitious program to genotype existing research studies in six major common diseases, and combine the results with clinical data to create a significant new resource for genetic researchers. The network’s goal is to help find genetic causes for common diseases, and its initial efforts focused on Attention Deficit Hyperactivity Disorder, diabetic nepropathy in type I diabetes, major depression, psoriasis, schizophrenia, and bipolar disorder. The resulting data are being deposited in a database within the National Library of Medicine at NIH, funded by GAIN, for the broad use of the research community. By comparing the genetic makeup of healthy people with that of people with the disease, scientists should be better able to target diagnosis, treatment, and prevention strategies. Originators of the initial studies have received additional grants to make their own analyses. Managed by the Foundation for NIH, GAIN combines the resources and expertise of several public and private entities to streamline the genetic research process. The program’s protocols for protecting participant privacy and confidentiality have served as a model for similar studies across the scientific community. The Foundation for NIH has raised $26 million for the network in cash and in-kind resources, primarily from Pfizer Inc and Affymetrix, Inc. Partners in GAIN include Abbott Laboratories Affymetrix, Inc. Broad Institute of the Massachusetts Institute of Technology and Harvard University Perlegen Sciences, Inc. Pfizer Inc GAIN has genotyped over 18,000 samples in six major common diseases in less than 18 months. Foundation for the National Institutes of Health www.fnih.org | 9
Page 1 and 2: 007 ANNUAL REPORT PARTNERS FOR INNO
Page 3 and 4: The Foundation for the National Ins
Page 5 and 6: MAY 2008 Dear Friends: 2007 was esp
Page 7 and 8: Global Health Security Initiative T
Page 9 and 10: The Biomarkers Consortium Contribut
Page 11: Osteorarthritis Initiative In 2007,
Page 15 and 16: GCGH: Grand Challenges in Global He
Page 17 and 18: GHSI: Global Health Security Initia
Page 19 and 20: Collaborative Summit on Breast Canc
Page 21 and 22: Targeted Cancer Therapies Tutorials
Page 23 and 24: Measures for Clinical Trials of Tre
Page 25 and 26: Foundation for NIH Supports Numerou
Page 27 and 28: Endowments at the Foundation for NI
Page 29 and 30: 2007 REVENUES Contributions 24% Gra
Page 31 and 32: Donors $5,000,000+ Bill & Melinda G
Page 33 and 34: Donors $100-$249 Anonymous (4) The
Page 35 and 36: Donors Monika Last Carl Julian Laut
Page 37 and 38: Advisory Boards Grand Challenges in
Page 39 and 40: Advisory Boards Ross Prentice, Ph.D
Page 41 and 42: Realizing the aims of foundation in

2007 Annual Report - Foundation for the National Institutes of Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?